SCHEMBL484627

SCHEMBL484627

CC(C)(C)OC(=O)N1CCC2(CCN(c3ccc(C#N)cc3)CC2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.53
EGLN2 Q96KS0 2/20 0.49
GPR119 Q8TDV5 6/20 0.47
GPR183 P32249 1/20 0.47
CYP3A4 P08684 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2D6 P10635 2/20 0.46
USP2 O75604 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
RET P07949 1/20 0.46
MAPK1 P28482 2/20 0.45
HSD17B10 Q99714 1/20 0.45
AR P10275 1/20 0.45
SCD5 Q86SK9 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HDAC2 Q92769 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18357677 0.93 EGLN2 (0.54) CYP11B2EGLN2GPR119GPR183CYP3A4
SCHEMBL22914768 0.91 EGLN2 (0.54) CYP11B2EGLN2GPR119GPR183CYP3A4
SCHEMBL22914827 0.89 EGLN2 (0.52) EGLN2GPR119GPR183CYP3A4CYP2C19
SCHEMBL22914845 0.85 EGLN2 (0.63) EGLN2GPR119GPR183ALDH1A1LMNA
SCHEMBL484886 0.84 CYP11B2 (0.55) CYP11B2GPR119CYP3A4CYP2C19CYP2D6
SCHEMBL30769248 0.84 CYP11B2 (0.55) CYP11B2GPR119CYP3A4CYP2C19CYP2C9
SCHEMBL485607 0.84 HDAC2 (0.58) CYP11B2GPR119CYP3A4CYP2C19CYP2C9
SCHEMBL2471189 0.84 MAPT (0.62) EGLN2GPR119CYP2C19ALDH1A1LMNA
SCHEMBL21520719 0.84 RET (0.58) CYP11B2EGLN2RET
SCHEMBL485392 0.83 CYP11B2 (0.54) CYP11B2GPR119CYP3A4CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 EP disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN CYP11B2 2150/4885EGLN2 1192/4885GPR119 206/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN CYP11B2 2150/4885EGLN2 1192/4885GPR119 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.